Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multinational, Phase 1/2 Study of the Safety and Dose Escalation of SHP648, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing FIX Padua in Hemophilia B Subjects

NCT04394286 is registered in ClinicalTrials.gov with Baxalta now part of Shire as lead sponsor.

NCT NCT04394286
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04394286 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multinational, Phase 1/2 Study of the Safety and Dose Escalation of SHP648, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing FIX Padua in Hemophilia B Subjects
Lead sponsor
Baxalta now part of Shire
Phase
Phase 1/2
Overall status
Terminated
Start date
May 13, 2020
Completion date
May 3, 2021
Enrollment
2 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia b